Retatrutide – 5mg

Retatrutide, the investigational compound being developed by Eli Lilly, is a novel triple agonist medication that targets GIP, GLP-1, and glucagon receptors simultaneously. This triple-action mechanism aims to provide enhanced metabolic benefits beyond those seen with dual agonists like tirzepatide. Early clinical trials have shown promising results for both weight loss and glycemic control, with some studies suggesting potentially greater efficacy than existing treatments. Retatrutide works by improving insulin sensitivity, reducing appetite, increasing energy expenditure, and altering fat metabolism through its triple-hormone approach.